The ex vivo results suggest that highly selective FLT3 inhibitors have more prominent responses in FLT3-ITD+ AML patients with high ITD-AR regardless of disease stage, while patients with low ITD-AR show stronger responses to non-selective kinase inhibitors targeting FLT3 (e.g. midostaurin). Here, AR is linked to acute myeloid leukemia.